Status:
UNKNOWN
Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients
Lead Sponsor:
Indonesia University
Conditions:
COVID
Pulmonary Infection
Eligibility:
All Genders
18-95 years
Phase:
PHASE1
Brief Summary
Novel Coronavirus (2019nCoV) or Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) that causes Coronavirus Disease 2019, or known as Covid-19 has recently become a global health emergency si...
Detailed Description
This study is a double blind, randomized control trial (RCT). This study will be concluded in 2 months, from May to July 2020, from subject selection to the end of follow up. Research subjects are obt...
Eligibility Criteria
Inclusion
- Patients aged 18-95 years old
- Confirmed for diagnosis of Covid-19 through RT-PCR from nasopharyngeal swab and/or bronchoalveolar lavage for patients under intubation
- Laboratory results showed leukopenia and lymphopenic
- Chest radiography shows pneumonia appearance and/or ground-glass opacity on chest CT-Scan
- Patients/their families are willing to sign the informed consent
Exclusion
- History of malignancy
- Pregnant, or show positive result on pregnancy test
- Patients was/are currently participating in other clinical trials within the last 3 months
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04457609
Start Date
July 1 2020
End Date
September 1 2020
Last Update
July 7 2020
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Persahabatan General Hospital
Jakarta, DKI Jakarta, Indonesia
2
Sulianti Saroso Center for Infectious Disease
Jakarta, DKI Jakarta, Indonesia
3
Cipto Mangunkusumo General Hospital
Jakarta Pusat, DKI Jakarta, Indonesia
4
Universitas Indonesia Hospital
Depok, West Java, Indonesia